Furthermore, the IMpower110 trial, carried out in 2020, suggests that atezolizumab may serve as an first-line treatment for patients with NSCLC exhibiting PD-L1 expression, regardless of their tumor’s histological subtype (40). Here, CD274 is linked to neoplasm.